Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes : EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. / Tomaszewska, Agnieszka; Jagasia, Madan; Beohou, Eric; van der Werf, Steffie; Blaise, Didier; Kanfer, Edward; Milpied, Noel; Reményi, Péter; Ciceri, Fabio; Bourhis, Jean H.; Chevallier, Patrice; Solano, Carlos; Socié, Gerard; Bruno, Benedetto; Rambaldi, Alessandro; Castagna, Luca; Kröger, Nicolaus; Corradini, Paolo; Afanasyev, Boris; Ladetto, Marco; Niederwieser, Dietger; Scheid, Christof; Sengeloev, Henrik; Kroschinsky, Frank; Yakoub-Agha, Ibrahim; Schoemans, Helene; Koenecke, Christian; Penack, Olaf; Perić, Zinaida; Greinix, Hildegard; Duarte, Rafael F.; Basak, Grzegorz W.
I: Frontiers in Immunology, Bind 11, 613954, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes
T2 - EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
AU - Tomaszewska, Agnieszka
AU - Jagasia, Madan
AU - Beohou, Eric
AU - van der Werf, Steffie
AU - Blaise, Didier
AU - Kanfer, Edward
AU - Milpied, Noel
AU - Reményi, Péter
AU - Ciceri, Fabio
AU - Bourhis, Jean H.
AU - Chevallier, Patrice
AU - Solano, Carlos
AU - Socié, Gerard
AU - Bruno, Benedetto
AU - Rambaldi, Alessandro
AU - Castagna, Luca
AU - Kröger, Nicolaus
AU - Corradini, Paolo
AU - Afanasyev, Boris
AU - Ladetto, Marco
AU - Niederwieser, Dietger
AU - Scheid, Christof
AU - Sengeloev, Henrik
AU - Kroschinsky, Frank
AU - Yakoub-Agha, Ibrahim
AU - Schoemans, Helene
AU - Koenecke, Christian
AU - Penack, Olaf
AU - Perić, Zinaida
AU - Greinix, Hildegard
AU - Duarte, Rafael F.
AU - Basak, Grzegorz W.
N1 - Publisher Copyright: © Copyright © 2021 Tomaszewska, Jagasia, Beohou, van der Werf, Blaise, Kanfer, Milpied, Reményi, Ciceri, Bourhis, Chevallier, Solano, Socié, Bruno, Rambaldi, Castagna, Kröger, Corradini, Afanasyev, Ladetto, Niederwieser, Scheid, Sengeloev, Kroschinsky, Yakoub-Agha, Schoemans, Koenecke, Penack, Perić, Greinix, Duarte and Basak.
PY - 2021
Y1 - 2021
N2 - Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001–2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1–77.3) and 43.2 months (range 0.3–179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.
AB - Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001–2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1–77.3) and 43.2 months (range 0.3–179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.
KW - B-cell malignancy
KW - conditioning
KW - graft-versus-host disease
KW - non-relapse mortality after hematopoietic cell transplantation
KW - rituximab
KW - transplantation
U2 - 10.3389/fimmu.2020.613954
DO - 10.3389/fimmu.2020.613954
M3 - Journal article
C2 - 33603743
AN - SCOPUS:85100874273
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 613954
ER -
ID: 302073649